DJIA 17,672.60 -141.38 -0.79%
NASDAQ 4,757.88 7.48 0.16%
S&P 500 2,051.82 -11.33 -0.55%
market minute promo

ImmunoGen (NASDAQ: IMGN)

6.33 0.26 (4.28%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

IMGN $6.33 4.28%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $6.23
Previous Close $6.07
Daily Range $6.01 - $6.34
52-Week Range $5.34 - $17.80
Market Cap $544.0M
P/E Ratio -6.32
Dividend (Yield) $0.00 (0.0%)
Volume 1,896,126
Average Daily Volume 2,167,704
Current FY EPS -$0.72





ImmunoGen (IMGN) Description

ImmunoGen develops cancer therapeutics through its tumor-activated, prodrug technology, which targets antibodies with cancer-killing drugs. Website:

News & Commentary

Why ImmunoGen, Inc. Stock Was Decimated in December

ImmunoGen was the worst biotech stock in December after it and its partner Roche released disappointed study data. Find out whether the mauling was merited or if ImmunoGen shares could be a bargain here.

ImmunoGen: MARIANNE Failed? A Hair Raising Perspective

Perilous Reversal Stock: Immunogen (IMGN)

13 Analyst Stocks at $10 and Under With Huge Implied Upside

3 Value Stocks Near 52-Week Lows Worth Buying

These three value stocks have been beaten up recently, but there's a chance they may not stay near their 52-week lows for much longer.

ImmunoGen/Roche's Kadcyla Fails in Study, Shares Plunge - Analyst Blog

Roche Loses A Little Luster Before Year-End

Immunogen (IMGN) Showing Signs Of A Dead Cat Bounce Today

The 52-Week Low Club for Friday

Why ImmunoGen Inc. Stock Was Throttled

ImmunoGen shares lose half their value following an update on a key breast cancer drug trial. Find out whether today's swoon could mark a buying opportunity.

See More IMGN News...

IMGN's Top Competitors

IMGN $6.33 (4.28%)
Current stock: IMGN
GILD $105.54 (0.38%)
Current stock: GILD
AMGN $159.81 (0.15%)
Current stock: AMGN
BIIB $357.63 (1.13%)
Current stock: BIIB